NASDAQ:FLGT Fulgent Genetics (FLGT) Stock Price, News & Analysis $24.66 -0.19 (-0.76%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$24.65 -0.01 (-0.04%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Fulgent Genetics Stock (NASDAQ:FLGT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fulgent Genetics alerts:Sign Up Key Stats Today's Range$24.35▼$25.0150-Day Range$18.66▼$26.1552-Week Range$13.46▼$31.04Volume262,096 shsAverage Volume386,875 shsMarket Capitalization$689.00 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingReduce Company Overview Fulgent Genetics, Inc. is a diagnostics and therapeutics company that provides genetic testing and other laboratory services. Its offerings include tests for inherited conditions, cancer and infectious diseases, as well as pathology services for healthcare providers and health systems. Founded in 2011 and headquartered in Temple City, California, the company expanded its diagnostic capabilities through its 2021 acquisition of Inform Diagnostics, a provider of specialized pathology services. Fulgent also conducts research and development focused on precision therapies, including potential cancer treatments. Founder Ming Hsieh serves as Fulgent Genetics’ chief executive officer. The company serves customers in the United States and participates in international markets through its diagnostic operations.AI Generated. May Contain Errors. Read More Fulgent Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreFLGT MarketRank™: 1.641605648535 of 5 starsFulgent Genetics scored higher than 33% of companies evaluated by MarketBeat, and ranked 755th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingReduce Consensus RatingFulgent Genetics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Fulgent Genetics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageFulgent Genetics has only been the subject of 2 research reports in the past 90 days.Read more about Fulgent Genetics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fulgent Genetics are expected to grow in the coming year, from ($3.48) to ($2.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulgent Genetics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulgent Genetics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulgent Genetics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.32% of the float of Fulgent Genetics has been sold short.Short Interest Ratio / Days to CoverFulgent Genetics has a short interest ratio ("days to cover") of 7.81.Change versus previous monthShort interest in Fulgent Genetics has recently decreased by 5.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulgent Genetics does not currently pay a dividend.Dividend GrowthFulgent Genetics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.49 News SentimentFulgent Genetics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Fulgent Genetics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for FLGT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Fulgent Genetics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fulgent Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $117,156.00 in company stock.Percentage Held by Insiders36.18% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.06% of the stock of Fulgent Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulgent Genetics' insider trading history. Receive FLGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLGT Stock News HeadlinesFulgent Genetics Earnings Call Shows Improving Losses1 hour ago | tipranks.comFulgent Genetics (NASDAQ:FLGT) Stock Price Expected to Rise, Piper Sandler Analyst SaysNovember 12 at 2:13 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)Fulgent Genetics, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 10, 2026 | seekingalpha.comFulgent Genetics (NASDAQ:FLGT) Stock Jumps 20.3% After Strong EarningsNovember 8, 2026 | americanbankingnews.comFulgent Genetics (NASDAQ:FLGT) Upgraded to "Hold" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comFulgent Genetics (FLGT) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | finance.yahoo.comFulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comSee More Headlines FLGT Stock Analysis - Frequently Asked Questions How have FLGT shares performed this year? Fulgent Genetics' stock was trading at $26.27 on January 1st, 2026. Since then, FLGT stock has decreased by 6.1% and is now trading at $24.66. How were Fulgent Genetics' earnings last quarter? Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.56. The business had revenue of $90.41 million for the quarter, compared to analysts' expectations of $86.30 million. Fulgent Genetics had a negative trailing twelve-month return on equity of 5.66% and a negative net margin of 27.53%. Read the conference call transcript. Does Fulgent Genetics have any subsidiaries? The following companies are subsidiaries of Fulgent Genetics: Inform Diagnostics, CSI, Cytometry Specialists Inc., FF Gene Biotech, Fulgent Investment Development Limited, and Fulgent Therapeutics LLC. When did Fulgent Genetics IPO? Fulgent Genetics (FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers. Who are Fulgent Genetics' major shareholders? Fulgent Genetics' top institutional shareholders include State Street Corp (1.85%), Caxton Associates LLP (0.47%), Russell Investments Group Ltd. (0.31%) and Alps Advisors Inc. (0.13%). Insiders that own company stock include Hanlin Gao, Ming Hsieh, Jian Xie and Paul Kim. View institutional ownership trends. How do I buy shares of Fulgent Genetics? Shares of FLGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulgent Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulgent Genetics investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Tesla (TSLA), Trade Desk (TTD), Block (XYZ), Pinterest (PINS) and Appian (APPN). Company Calendar Last Earnings11/05/2026Today11/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 FLGT's financial health is in the Green zone, according to TradeSmith. FLGT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:FLGT CIK1674930 Webwww.fulgentgenetics.com Phone(626) 350-0537Fax626-454-1667Employees1,315Year Founded2011Price Target and Rating Average Price Target for Fulgent Genetics$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+1.4%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($3.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.51 million Net Margins-27.53% Pretax Margin-29.97% Return on Equity-5.66% Return on Assets-5.16% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual Sales$322.67 million Price / Sales2.14 Cash FlowN/A Price / Cash FlowN/A Book Value$35.24 per share Price / Book0.70Miscellaneous Outstanding Shares27,940,000Free Float17,831,000Market Cap$689.00 million OptionableOptionable Beta1.00 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:FLGT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulgent Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulgent Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
